Journal Article

Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trial

Tumusiime, Beatrice, Kurniawan, Sandy, Sari, Intan Permata, Rini, Ni Made, Espiritu-Villasfer, Rose Ann A., Ankunda, Rogers, Aprillia, Catharina, Bayas, Genevieve V., Nabisere, Ruth Mirembe, Lu, Qingshu, Kurniawan, Kristo, Aditia, Dedy, Uanithirat, Anuntaya, Cruz, Elsie Marie B. Dela, Katusiime, Assumpta, Ruslami, Rovina, Kurniawan, Randy D., Larasmanah, Alamanda, Veto, Rholine S, Pandey, Sushil, Sangsuk, Kaewta, Santoso, Prayudi, Rivera, Krizia Chloe R., Sekaggya-Wiltshire, Christine, Shivani, Hafirain, Jihaan, Caoili, Janice, Otaalo, Brian, Crook, Angela M., Phelan, Jody, Ihsan, Naufal, Effendi, Tiar Oktavian, Rutkute, Kristina, Cagwin, Rose Marie L., Najjemba, Letisha, Mungklang, Pornkhaun, Lugemwa, Abbas, Belarosa, Diadikma, Gatechompol, Sivaporn, Jirajariyavej, Supunnee, Bhalla, Manpreet, Panenggak, Nur S.R., Rattanawai, Sirijit, Mukhlis, A. Siti Kahfiah, Balane, Glenn Ibana, Nampala, Juliet, Kaguiri, Eunice, Chew, Ka Lip, Paton, Nicholas I, Kityo, Cissy, Papineni, Padmasayee, Isbaniah, Fathiyah, Ureaphongsukkit, Thornthun, Serumaga, Timothy Arthur, Bin Abdul Muttalif, Abdul Razak, Cousin

2025

Overview

WHO recommends a 2-month optimal duration for new drug regimens for rifampicin-susceptible tuberculosis. We aimed to investigate the efficacy and safety of the 8-week regimens that were assessed as part of the TRUNCATE management strategy of the TRUNCATE-TB trial. TRUNCATE-TB was a multi-arm, multi-stage, open-label, randomised controlled trial in which participants aged 18–65 years with rifampicin-susceptible pulmonary tuberculosis were randomly assigned via a web-based system, using permuted blocks, to 24-week standard treatment (rifampicin, isoniazid, pyrazinamide, and ethambutol) or the TRUNCATE management strategy comprising initial 8-week treatment, then post-treatment monitoring and re-treatment where needed. The four 8-week regimens comprised five drugs, modified from standard treatment: high-dose rifampicin and linezolid, or high-dose rifampicin and clofazimine, or bedaquiline and linezolid, all given with isoniazid, pyrazinamide, and ethambutol; and rifapentine, linezolid, and levofloxacin, given with isoniazid and pyrazinamide. Here, we report the efficacy (proportion with unfavourable outcome; and difference from standard treatment, assessed via Bayesian methods) and safety of the 8-week regimens, assessed in the intention-to-treat population. This prespecified exploratory analysis is distinct from the previously reported 96-week outcome of the strategy in which the regimens were deployed. This trial is registered with ClinicalTrials.gov (NCT03474198). Between March 21, 2018, and March 26, 2020, 675 participants (674 in the intention-to-treat population) were enrolled and randomly assigned to the standard treatment group or one of the four 8-week regimen groups. Two 8-week regimens progressed to full enrolment. An unfavourable outcome (mainly relapse) occurred in seven (4%) of 181 participants on standard treatment; 46 (25%) of 184 on the high-dose rifampicin and linezolid-containing regimen (adjusted difference 21·0%, 95% Bayesian credible interval [BCI] 14·3–28·1); and 26 (14%) of 189 on the bedaquiline and linezolid-containing regimen (adjusted difference 9·3% [4·3–14·9]). Grade 3–4 adverse events occurred in 24 (14%) of 181 participants on standard treatment, 20 (11%) of 184 on the rifampicin-linezolid regimen, and 22 (12%) of 189 on the bedaquiline-linezolid regimen. Efficacy was worse with 8-week regimens, although the difference from standard treatment varied between regimens. Even the best 8-week regimen (bedaquiline-linezolid) should only be used as part of a management strategy involving post-treatment monitoring and re-treatment if necessary. Singapore National Medical Research Council; UK Department of Health and Social Care; UK Foreign, Commonwealth, and Development Office; UK Medical Research Council; Wellcome Trust; and UK Research and Innovation Medical Research Council.

• Publisher: Elsevier Ltd,Elsevier Limited
• Subject: Adolescent / Adult / Aged / Antitubercular Agents - administration & dosage / Antitubercular Agents - adverse effects / Antitubercular Agents - therapeutic use / Bayesian analysis / Clinical outcomes / Clofazimine / Clofazimine - administration & dosage / Clofazimine - therapeutic use / Diarylquinolines - administration & dosage / Diarylquinolines - therapeutic use / Drug Administration Schedule / Drug dosages / Drug Therapy, Combination / Effectiveness / Ethambutol / Ethambutol - administration & dosage / Ethambutol - therapeutic use / Female / Humans / Hypotheses / Infectious Disease / Isoniazid / Isoniazid - administration & dosage / Isoniazid - therapeutic use / Labels / Levofloxacin / Linezolid / Linezolid - administration & dosage / Linezolid - therapeutic use / Male / Medical innovations / Medical research / Middle Aged / Monitoring / Mycobacterium tuberculosis - drug effects / Pyrazinamide / Pyrazinamide - administration & dosage / Pyrazinamide - therapeutic use / Rifampin / Rifampin - administration & dosage / Rifampin - adverse effects / Rifampin - therapeutic use / Safety / Telemedicine / Treatment Outcome / Tuberculosis / Tuberculosis, Pulmonary - drug therapy / Tuberculosis, Pulmonary - microbiology / Young Adult